Pediatric Vaccines and Vaccine Injury Claims: A Medicolegal Guide for Attorneys

These scenarios illustrate the fundamentally different pathways that vaccine-related claims follow — and why attorneys must understand both the science of vaccine safety and the unique legal framework governing vaccine injury claims in the United States. This article provides an evidence-based overview to help attorneys evaluate the medical and legal issues in cases involving pediatric vaccines, including a dedicated discussion of shoulder injury related to vaccine administration (SIRVA), one of the fastest-growing categories of vaccine injury claims.

A Threshold Point: Vaccine Injury Claims Are Not Ordinary Malpractice Claims

Before analyzing any vaccine-related case, attorneys must understand that vaccine injury claims in the United States occupy a unique legal channel that differs fundamentally from standard medical malpractice litigation.

The National Vaccine Injury Compensation Program (VICP), established in 1988, is a no-fault federal system created as an alternative to civil litigation and to simplify the process of settling vaccine injury claims. Under this program, individuals who believe they have been injured by a covered vaccine must first file a claim with the VICP before pursuing civil litigation against manufacturers or vaccine providers.

Key features of the VICP that every attorney should know:

• No-fault system. The claimant does not need to prove negligence. Compensation may be sought if a person believes they experienced an injury as a result of a vaccine listed on the Vaccine Injury Table.
• Covered vaccines. The VICP covers vaccines routinely recommended for children and adolescents. The vaccine recipient and beneficiary can be of any age. Vaccines not routinely recommended for children — including zoster vaccine, pneumococcal polysaccharide vaccine (PPSV23), and most travel vaccines — are not covered.
• Pregnancy coverage. The 21st Century Cures Act (2016) extended coverage to vaccines recommended for routine use in pregnant people, covering both the pregnant person and the child who was in utero at the time.
• Filing deadlines. Claims must be filed within 36 months after the first symptom appeared following immunization. Death claims must be filed within 2 years of the death and within 4 years after the first symptom of the vaccine injury that resulted in death.
• The election. If the claimant accepts the VICP judgment, neither the vaccine provider nor the manufacturer can be sued in civil litigation. If the claimant rejects the VICP judgment, they may then file a civil claim — though this seldom happens.
• Attorney's fees. To ensure legal costs are not a barrier, the VICP may pay attorney's fees and other legal costs regardless of the outcome, provided the claim was filed on a reasonable basis and in good faith.

This structure means that the majority of alleged vaccine injuries are adjudicated in the U.S. Court of Federal Claims (the "Vaccine Court") rather than in state malpractice courts. Understanding which claims fall inside the VICP and which fall outside it is the first analytical step in any vaccine-related case.

The Vaccine Injury Table

Central to the VICP is the Vaccine Injury Table, which lists specific vaccines and the injuries, disabilities, illnesses, and conditions presumed to be caused by each vaccine when they occur within a specified time interval after vaccination.

For a "Table injury" — an injury listed on the Table that occurs within the designated time window — causation is presumed, and the claimant does not need to prove that the vaccine caused the injury. Examples of Table injuries include anaphylaxis within a short time window after certain vaccines, vaccine-strain viral disease in specified circumstances, and shoulder injury related to vaccine administration (SIRVA), which was added to the Table in 2017.

For an injury not listed on the Table, or one occurring outside the specified interval, the claimant must prove causation ("causation in fact") — typically requiring expert medical testimony to establish a biologically plausible mechanism, a logical sequence of cause and effect, and an appropriate temporal relationship.

The Table is periodically revised as scientific evidence evolves. Conditions have been both added and removed as epidemiologic evidence accumulates. Notably, the status of SIRVA on the Table has itself been the subject of regulatory rulemaking, and attorneys should verify the current Table at the time of any case evaluation.

Genuine Vaccine Adverse Events: What the Evidence Establishes

Attorneys must distinguish between adverse events that are scientifically established as caused by vaccines and those that are not. The evidence base is extensive. A comprehensive systematic review evaluating 46 adverse events following immunization found a causal relationship with at least one routinely administered U.S. vaccine established for 12 adverse events.

These scientifically established vaccine reactions are:

• Anaphylaxis — a severe allergic reaction, estimated at approximately 1 case per million doses. Fatalities from vaccine-induced anaphylaxis are exceedingly rare.
• Febrile seizures — associated with fever-inducing vaccines such as MMR, influenza, and pneumococcal conjugate vaccine. The attributable risk is approximately 3.92 per 100,000 for vaccines given to infants aged 3–5 months. Importantly, febrile seizures are generally benign and self-limited.
• Guillain-Barré syndrome — very rarely following influenza vaccine in adults (approximately 1–3 per million vaccinations).
• Immune thrombocytopenic purpura (ITP) — following MMR vaccine, estimated at 1–3 per 100,000.
• Arthralgia or arthritis — mild, acute, and transient (not chronic), most commonly in adult women after rubella-containing vaccine.
• Deltoid bursitis — when the vaccine is administered improperly (an administration/injection-technique injury; see the SIRVA section below).
• Syncope — fainting, particularly in adolescents, which is why post-vaccination observation is recommended.
• Encephalitis — very rarely following measles vaccine.
• Disseminated varicella infection, hepatitis, and herpes zoster — from the live varicella vaccine, occurring rarely and primarily in individuals with immune deficiencies for whom the vaccine is contraindicated.
• Meningitis

Other than mild, transient arthralgia, all of these established reactions are rare (approximately 0.01–0.1%) or very rare (<0.01%). An updated systematic review and meta-analysis of 338 studies reached similar conclusions: across a large body of research, there were few associations between vaccines and serious adverse events.

Disproven Associations: Autism and Neurodevelopmental Injury

Attorneys will frequently encounter families who attribute autism spectrum disorder (ASD) or other neurodevelopmental conditions to vaccines. The scientific evidence on this question is definitive and must be clearly understood.

The scientific literature does not support an association between vaccination and ASD. The American Academy of Pediatrics states unequivocally that epidemiological studies do not demonstrate any association of the MMR vaccine, mercury exposure by thimerosal-containing vaccines, aluminum in vaccines, or the cumulative number of vaccines with ASD.

The evidence includes:

• A 2014 meta-analysis of five cohort studies involving 1,256,407 children and five case-control studies involving 9,920 children found no relationship between vaccination and autism (odds ratio 0.99), and no association with MMR, thimerosal, or mercury specifically.
• Studies demonstrate that MMR is not associated with increased ASD risk even among children at higher genetic risk because of having an older sibling with ASD.
• Vaccines used for children in the United States have not contained thimerosal since 2001, yet ASD diagnoses continued to rise — a pattern inconsistent with a causal role.
• A recent study of more than 1.2 million children in Denmark found no link between cumulative aluminum exposure from the childhood immunization schedule and ASD or other neurodevelopmental outcomes, and no dose-response relationship.
• The observed increase in ASD diagnoses is largely attributable to broadening diagnostic criteria, diagnostic substitution, and changes in screening practices; ASD has high heritability (64%–91%), and converging evidence suggests it originates in utero, making postnatal exposures unlikely causes.

A landmark systematic review characterized the evidence on autism as particularly strong — repeated studies by different investigators, using varied and robust methods across different populations, all unable to reject the null hypothesis — supporting the conclusion that childhood vaccines do not cause autism. Notably, claims that MMR caused autism were adjudicated and rejected in the VICP's Omnibus Autism Proceeding.

For litigation, this distinction matters: the VICP and civil courts require scientifically reliable causation evidence, and claims premised on the vaccine-autism hypothesis lack the necessary evidentiary foundation.

Shoulder Injury Related to Vaccine Administration (SIRVA)

Shoulder injury related to vaccine administration (SIRVA) deserves separate and detailed discussion because it is one of the most rapidly growing categories of vaccine injury claims and because it sits at the intersection of vaccine science and traditional standard-of-care analysis.

What SIRVA Is — and Is Not

SIRVA is a medicolegal term rather than a specific medical diagnosis. It was introduced by the VICP after an increase in claims for vaccine-related shoulder injury and was added to the Vaccine Injury Table in 2017. It is generally defined as shoulder pain with limited range of motion occurring within 48 hours after vaccine receipt in a person with no prior history of pain, inflammation, or dysfunction of the affected shoulder before vaccination.

Importantly, in 2024 the National Academies of Sciences, Engineering, and Medicine (NASEM) reviewed shoulder injuries after vaccination and concluded that SIRVA "represents a clinical syndrome, is not a specific diagnosis, and may have a number of causes." Rather than treating "SIRVA" as a single entity, NASEM found a causal relationship between vaccine administration and four specific shoulder conditions when the injection is placed into the wrong tissue:

• Subacromial/subdeltoid bursitis
• Acute rotator cuff or acute biceps tendinopathy
• Bone injury
• Axillary or radial nerve injury

NASEM concluded that "these injuries are due to injection into the tissue resulting in the damage" — a mechanical, injection-technique mechanism, distinct from the older hypothesis of an immune-mediated inflammatory response, for which there is no confirmatory experimental evidence.

Mechanism and Injection Technique

SIRVA results from improper injection technique — most commonly, injecting too high on the arm (above the deltoid muscle mass) or too deep, so that vaccine and needle reach the subacromial/subdeltoid bursa, the joint, tendons, bone, or adjacent nerves rather than the body of the deltoid muscle. Analysis of VAERS reports has specifically identified administration too high in the deltoid as a contributing factor. This makes SIRVA distinct from most vaccine reactions: it is not a reaction to the vaccine's biologic content per se but a preventable consequence of how and where the injection was given. This mechanical, technique-dependent mechanism is precisely why SIRVA claims often implicate the standard of care for administration.

Clinical Presentation and Diagnosis

Patients typically present with severe shoulder pain and limited range of motion within 48 hours of vaccination, often with notable functional limitation. The most common associated diagnoses in the literature are subacromial bursitis, adhesive capsulitis ("frozen shoulder"), and rotator cuff pathology. On evaluation, soft-tissue abnormalities of the shoulder are the most common objective finding, and ultrasound frequently demonstrates bursal or soft-tissue changes; MRI may be used to characterize rotator cuff, bursal, or bone involvement. A systematic review distinguished three categories of post-vaccination shoulder problems that attorneys and experts should keep separate: (1) local inflammatory injury (the classic SIRVA picture), (2) brachial neuritis (Parsonage-Turner syndrome), and (3) direct nerve injury — the latter two typically confirmed with electromyography/nerve conduction studies.

Epidemiology and Demographics

SIRVA is rare. The best-available comparative data estimate an occurrence of approximately 1 in 130,000 vaccination events, and SIRVA accounts for slightly less than 0.5% of all reports to VAERS. It is most commonly reported among adult women (roughly three-quarters of reported cases) with a median age around 50 years, and it is rarely reported in children. This demographic point is significant for a pediatric-focused practice: while SIRVA can occur at any age, pediatric SIRVA claims are uncommon, and adolescent claims are more likely than those involving young children. Reported prevalence varies widely by methodology; a survey of hospital workers after COVID-19 vaccination estimated symptomatic shoulder complaints in approximately 3% of respondents, illustrating how ascertainment method affects estimates.

Treatment and Prognosis

Most cases are managed nonoperatively — physical or occupational therapy, NSAIDs, and corticosteroid injections — and outcomes are generally favorable, with the majority of patients improving without residual deficit. Early corticosteroid injection has been associated with faster symptom resolution in small case series. However, recovery can be prolonged: CDC data cited in the literature indicate that roughly 65% of patients have pain lasting longer than 1 month and about 25% longer than 3 months, and reported full-resolution rates across studies vary widely (2.9% to 56%). Surgery is rarely required and is generally reserved for persistent structural pathology such as rotator cuff or biceps tendon injury. A minority of patients report ongoing disability. For nerve-related injuries (brachial neuritis or direct nerve injury), treatment is typically nonoperative, and most patients improve over months, though some retain residual weakness.

Why SIRVA Matters in Litigation

SIRVA is unusual among vaccine claims because it often turns on how the vaccine was administered rather than on the vaccine itself. As a Table injury (subject to the current Table), it may proceed through the VICP with a presumption of causation when the definitional criteria and time window are met. At the same time, because the underlying mechanism is faulty injection technique, SIRVA claims frequently raise classic standard-of-care questions: Was the injection site correctly identified? Was the needle length and angle appropriate for the patient's body habitus? Was the vaccinator adequately trained? Documentation of the injection site, needle length, technique, and the vaccinator's training is therefore central to evaluating these cases.

How Causation Is Evaluated

Establishing whether a vaccine actually caused an adverse event requires rigorous methodology — and attorneys should understand why a temporal association alone is insufficient.

Key principles of vaccine causation analysis:

• Temporal association is not causation. The fact that an event occurred after a vaccine — even with a proposed biological mechanism — does not establish that the vaccine caused it. Because millions of children are vaccinated, some will coincidentally develop unrelated conditions in the days and weeks afterward.
• VAERS is hypothesis-generating, not causation-testing. The Vaccine Adverse Event Reporting System (VAERS) accepts reports from anyone and suffers from underreporting, overreporting, absence of denominators, and no unvaccinated comparison group. It cannot be used to assess statistical associations between vaccines and adverse events. Attorneys should be cautious of expert opinions that rely on VAERS reports as proof of causation.
• The Vaccine Safety Datalink (VSD) can test causation. The VSD — a collaboration between the CDC and integrated health care organizations — uses electronic health records to compare vaccinated and unvaccinated populations using case-control and self-controlled case series methods. It has both confirmed rare true associations (e.g., MMR and ITP; MMRV and febrile seizures) and demonstrated the absence of association for many purported adverse events.
• A single study is usually insufficient to establish a causal relationship; replication across methods and populations is the standard.
• The WHO causality assessment framework classifies individual adverse events following immunization as consistent, inconsistent, indeterminate, or unclassifiable with respect to a causal association — providing a standardized approach used internationally.

For non-Table injuries in the VICP, claimants generally must satisfy a three-pronged causation test derived from case law: a medical theory connecting the vaccine to the injury, a logical sequence of cause and effect, and a proximate temporal relationship — a framework distinct from, and in some respects more claimant-friendly than, the causation standards applied in ordinary civil litigation.

Claims That Fall Outside the VICP: Administration and Standard-of-Care Issues

While the VICP covers injuries alleged to result from the vaccine itself, certain claims involve alleged negligence in how a vaccine was handled, administered, or managed. These may fall outside the VICP's core coverage and can implicate traditional standard-of-care analysis. Examples include:

• Improper injection technique. SIRVA and deltoid bursitis result from injecting too high or too deep in the shoulder (discussed in detail above). Even though SIRVA is a Table injury, the underlying mechanism — faulty administration — makes these cases distinct from reactions to the vaccine's biologic content.
• Failure to observe for and manage anaphylaxis. Because anaphylaxis is a known, if rare, reaction occurring at roughly 1 per million doses, the standard of care includes preparedness to recognize and treat it — including immediate availability of epinephrine and appropriate post-vaccination observation. A clinic's failure to have epinephrine available or to respond promptly to anaphylaxis may constitute a deviation from the standard of care.
• Administration despite a contraindication. Some vaccines are contraindicated in specific populations — for example, live vaccines (such as varicella or MMR) in certain immunocompromised children. Administering a contraindicated live vaccine that results in disseminated infection may constitute a deviation from the standard of care.
• Informed consent and the Vaccine Information Statement (VIS). Federal law requires providers to distribute a VIS to the patient's legal representative every time a covered vaccine is administered. Importantly, the VIS alone is not considered informed consent — it is intended to facilitate, not replace, effective risk communication. State law controls consent requirements, including whether consent must be written and whether adolescents may consent for themselves. Documentation failures — failure to provide the VIS, failure to document consent — may be relevant to litigation.
• Wrong vaccine, wrong dose, wrong patient, or expired vaccine — classic medication-error claims that follow ordinary negligence analysis.
• Cold-chain and storage failures — administration of improperly stored vaccine that fails to confer immunity.

A Different Category: Failure-to-Vaccinate and Vaccine-Preventable Disease Claims

Attorneys may also encounter the inverse scenario — claims arising when a child was not vaccinated and subsequently contracted a vaccine-preventable disease (VPD). These cases involve entirely different considerations:

• The public health value of vaccination is substantial. Over the lifetime of a single U.S. birth cohort, routine childhood immunization was estimated to avert 17.8 million disease cases and 31,400 deaths.
• Higher rates of immunization exemptions in communities correlate with higher rates of vaccine-preventable illness and outbreaks, and unvaccinated children are often geographically clustered, amplifying outbreak risk.
• Vaccine refusal is associated with an increased risk of measles and pertussis, both among those who refuse vaccines and, through diminished herd immunity, among fully vaccinated individuals.

Such claims may arise in contexts involving alleged failure to recommend or administer indicated vaccines, disputes between parents over vaccination, or transmission to vulnerable individuals. These are fact-specific and jurisdiction-dependent.

Common Misconceptions

• "A bad outcome after a vaccine proves the vaccine caused it." A temporal relationship is not causation. Coincidental illnesses occur, and rigorous epidemiologic methods — not VAERS reports or temporal proximity — are required to establish causation.
• "Vaccines cause autism." The scientific evidence definitively does not support this. Multiple large studies across populations and methods, including a meta-analysis of over 1.2 million children, found no association.
• "SIRVA is a disease caused by the vaccine itself." SIRVA is a clinical syndrome, not a specific diagnosis, and is caused by improper injection into shoulder structures rather than by the vaccine's biologic content. It is largely preventable with correct technique.
• "The Vaccine Information Statement is the same as informed consent." False. The VIS is required but does not by itself constitute informed consent; it is meant to facilitate a risk discussion.
• "Every vaccine injury claim is a malpractice lawsuit." False. Most alleged vaccine injuries must first proceed through the no-fault VICP rather than through state malpractice courts.
• "Serious vaccine reactions are common." With the exception of mild, transient arthralgia after rubella vaccine, established serious vaccine reactions are rare (0.01–0.1%) or very rare (<0.01%). SIRVA occurs after roughly 1 in 130,000 vaccinations.

Medical Records That Often Matter

Thorough evaluation of a vaccine-related case depends on reviewing:

• Immunization records — the specific vaccine, manufacturer, lot number, dose, route, anatomic site, and date/time of administration
• Injection details for SIRVA claims — the documented injection site, needle length and gauge, injection angle, patient body habitus/positioning, and the vaccinator's role and training
• The Vaccine Information Statement documentation — which VIS edition was provided and when, and documentation of consent
• Pre-vaccination screening — documentation of contraindication screening (e.g., immunocompromise, prior reactions, allergies) and, for SIRVA, any pre-existing shoulder condition
• Clinical records of the alleged injury — including onset timing relative to vaccination, which is critical to Table-injury analysis (SIRVA generally requires onset within 48 hours with no prior shoulder dysfunction)
• Shoulder imaging and studies — ultrasound, MRI, and, where nerve injury is alleged, electromyography/nerve conduction studies
• Emergency and hospital records — for the evaluation and management of any acute reaction such as anaphylaxis
• Clinic emergency preparedness records — availability of epinephrine and emergency protocols, where an anaphylaxis-management claim is at issue
• Developmental and neurological records — including pre-existing conditions, family history, and the full trajectory of any alleged neurodevelopmental condition
• Prior medical history — to identify pre-existing or alternative causes

Long-Term Outcomes and Damages

Damages in vaccine-related cases depend entirely on the nature of the injury:

• Self-limited reactions (e.g., simple febrile seizures, transient arthralgia, uncomplicated anaphylaxis treated promptly) typically resolve without long-term sequelae, limiting damages.
• SIRVA and administration injuries — most cases improve with conservative treatment, but a meaningful minority experience prolonged pain (roughly 25% beyond 3 months) and some report ongoing disability. Damages may include physical/occupational therapy, corticosteroid injections, imaging, chronic pain, limited range of motion, lost work or school time, and, in a small subset, surgery.
• Serious injuries — such as anaphylaxis complicated by hypoxic-ischemic injury, disseminated infection from a contraindicated live vaccine, or Guillain-Barré syndrome with residual deficits — may involve substantial long-term damages including ongoing medical care, rehabilitation, reduced earning capacity, and pain and suffering.

Within the VICP, compensable damages include medical expenses, lost earnings, pain and suffering (subject to statutory caps), and, in death cases, a statutory death benefit. These differ from the damages available in civil litigation.

The Value of Pediatric and Immunization Expertise

Vaccine-related cases require expertise that spans clinical pediatrics, immunology, and the specialized epidemiology of vaccine safety. An experienced pediatric expert can assist attorneys by:

• Distinguishing scientifically established vaccine reactions from coincidental or disproven associations
• Distinguishing true SIRVA (a local injection-site injury) from brachial neuritis, direct nerve injury, and coincidental shoulder pathology
• Evaluating whether an alleged injury meets the criteria for a Table injury (including the SIRVA definition and time window) or requires proof of causation in fact
• Assessing whether the injection technique, site, and needle length met the standard of care
• Assessing the temporal relationship between vaccination and the alleged injury against known biological timelines
• Evaluating informed consent and VIS documentation
• Explaining why VAERS reports and temporal associations do not establish causation
• Providing objective, evidence-based opinions grounded in the vaccine safety literature

Because the vaccine safety literature is vast and continually evolving, and because the VICP framework is highly specialized, expertise in this specific area is essential to accurate case evaluation.

Key Takeaways for Attorneys

1. Vaccine injury claims are not ordinary malpractice claims. Most alleged injuries from covered vaccines must first proceed through the no-fault federal VICP before any civil suit.
2. Know the deadlines. VICP claims must generally be filed within 36 months of the first symptom; death claims within 2 years of death.
3. The Vaccine Injury Table is central. Table injuries carry a presumption of causation within specified time windows; off-Table claims require proof of causation. SIRVA was added to the Table in 2017, though its status has been subject to regulatory change and should be verified.
4. Established serious vaccine reactions are real but rare. Twelve adverse events are scientifically established as vaccine-caused, nearly all rare or very rare.
5. Vaccines do not cause autism. This is supported by definitive, replicated, large-scale evidence and has been rejected in the Vaccine Court.
6. SIRVA is a preventable injection-technique injury, not a reaction to the vaccine itself. It is a clinical syndrome (not a single diagnosis), occurs after roughly 1 in 130,000 vaccinations, is most common in adult women and rare in young children, and turns heavily on injection site, needle length, and vaccinator training.
7. Temporal association is not causation, and VAERS cannot prove causation. Reliable causation evidence comes from controlled epidemiologic studies such as the VSD.
8. Some claims fall outside the VICP. Administration errors, failure to manage anaphylaxis, administration of contraindicated vaccines, and informed-consent failures may implicate traditional standard-of-care analysis.
9. The VIS is not informed consent. It is required but is intended to facilitate, not replace, a risk discussion; state law governs consent.
10. Documentation is critical, and specialized expertise is essential. Lot numbers, VIS provision, contraindication screening, and — especially for SIRVA — injection site, needle length, and technique are frequently central to case evaluation. Vaccine cases require familiarity with both vaccine safety science and the unique VICP legal framework.